Common General Knowledge and Inconvenient Details - Accord v Medac and Unwired Planet from patlit.blogspot.com Two recent rulings of Mr Justice Birss of the Patents Court, England and Wales contain interesting statements on obviousness attacks based on common general knowledge alone, adding some new aspects to the findings of the ...
Share via E–mail | Twitter | Facebook
Will there be any full-time UK Patents Court judges in the UPC? from ipkitten.blogspot.com If no UK patents judges will be in the UPC, this paves the way for Judge Merpel, presiding....Like any Kat, Merpel is attuned to the slightest rustle or disturbance in the patent force. Her ...
Share via E–mail | Twitter | Facebook
Never Too Late: if you missed the IPKat last week from ipkitten.blogspot.com Did you miss the last week of IPKat? No need to worry - catch up with the 92nd instalment of Never Too Late today.* In Memoriam of Kay ChapmanIPKat remembers Kay Chapman's contributions to ... Share via E–mail | Twitter | Facebook
PTAB Statistics From Spring BIO IPCC Meeting from www.patentdocs.org By Kevin E. Noonan -- At the end of March, the Intellectual Property Counsels' Committee (IPCC) of the Biotechnology Innovation Organization (BIO) held its Spring meeting, convening in-house counsel and outside counsel involved in patenting the ...
Share via E–mail | Twitter | Facebook
Russia: New Amendments Would Allow Use Of Inventions Without Permission Of Patent Holders from www.ip-watch.org The Russian government is considering approval of a package of controversial amendments to national legislation that would allow the use of inventions without the permission of patent holders.
Share via E–mail | Twitter | Facebook
WIPO Committee Adopts New Development Projects, Agrees Future Work, Stumbles On Technical Assistance from www.ip-watch.org World Intellectual Property Organization committee members last week agreed some new development projects and advanced discussions on the agency’s development dimension, including technical assistance, technology transfer and ties to the United Nations Sustainable Development ...
Share via E–mail | Twitter | Facebook
Epic Trade Secret Case Billion Dollar Verdict from patentlyo.com by Dennis Crouch I expect that 2016 will be the year that Congress to creates a federal cause of action for trade secret misappropriation. Acting in rare unanimous fashion, the Senate recently passed the Defend ...
Share via E–mail | Twitter | Facebook
Pre-Suit Attorney Fees Recoverable Under 35 U.S.C. § 285 from docketreport.blogspot.com The court awarded a defendant $3.4 million in attorney fees under 35 U.S.C. § 285 and allowed it to recover $235,780 in pre-suit fees. "[Defendant's] billing entries reflect that it engaged ...
Share via E–mail | Twitter | Facebook
Pending Supreme Court Patent Cases 2016 (April 18 Update) from patentlyo.com by Dennis Crouch Cuozzo: Prof Mann provides his preview of the April 25 oral arguments in Cuozzo v. Lee; and Cuozzo has filed its reply brief. Neither document address my the mootness concern regarding Cuozzo ...
Share via E–mail | Twitter | Facebook
Motley Fool notes Phase 3 data for ocrelizumab being presented 17-21 April 2016 at AAN meeting from ipbiz.blogspot.com From the Fool:
Although a bit more expensive than AbbVie on a PEG ratio basis, Roche's rock solid product line is on more stable ground. That said, I feel it's about to launch ... Share via E–mail | Twitter | Facebook
Court Report from www.patentdocs.org By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Forest Laboratories, LLC et al. v. Amerigen Pharmaceuticals, Inc. et al. 1:15-cv-00966; filed October 23 ...
Share via E–mail | Twitter | Facebook
Public Health Organizations Urge Congress to Reject Trans-Pacific Partnership Agreement from www.patentdocs.org By Donald Zuhn -- In a letter sent to members of Congress earlier this month, 58 public health organizations urged Congress to reject the Trans-Pacific Partnership (TPP) in its current form, stating that the coalition was ...
Share via E–mail | Twitter | Facebook